SCHEMBL4319348

SCHEMBL4319348

Cc1ccc(C#Cc2ccccc2)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.55
CYP2C19 P33261 2/20 0.55
CYP2E1 P05181 1/20 0.55
CYP2A6 P11509 1/20 0.55
CYP2B6 P20813 1/20 0.55
GRM5 P41594 10/20 0.53
KMT2A Q03164 2/20 0.51
ATM Q13315 1/20 0.51
APP P05067 1/20 0.50
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
TP53 P04637 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
PKM P14618 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30772300 1.00 CYP1A2 (0.55) CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6
SCHEMBL14129687 0.85 GRM5 (0.61) CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6
SCHEMBL9952342 0.80 GRM5 (0.57) CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6
SCHEMBL9290564 0.78 CYP1A2 (0.58) CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6
SCHEMBL17705931 0.78 GRM5 (0.62) CYP1A2CYP2C19GRM5KMT2AAPP
SCHEMBL16289414 0.77 CYP1A2 (0.56) CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6
SCHEMBL989891 0.77 CYP1A2 (0.56) CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6
SCHEMBL12824425 0.77 CYP1A2 (0.56) CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6
SCHEMBL14129766 0.76 CYP1A2 (0.51) CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6
SCHEMBL4710401 0.76 GRM5 (0.69) CYP1A2CYP2C19GRM5KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325964-A1 Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression WYETH (US) 2009-12-31 US claimed
WO-2009143404-A1 PIPERAZINE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) NEGATIVE ALLOSTERIC MODULATORS FOR ANXIETY/DEPRESSION WYETH (US) 2009-11-26 WO claimed
CN-117430549-A Method for preparing isonicotinic acid compound by taking carbon dioxide as carboxyl source 南开大学 2024-01-23 CN disclosed
WO-2020149553-A1 ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR TREATMENT OF KINASE-RELATED DISEASE 주식회사 보로노이 2020-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325964-A1 Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression GRM5, GRIK5, GRM1 CYP1A2 4000/4885CYP2C19 3756/4885CYP2E1 4199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.